Tarsus Pharmaceuticals Inc (TARS) Stock Price, Quote & News

Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-0...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 418 1801

Website: tarsusrx.com

Address:

17700 Laguna Canyon Road, Floor 4, Irvine, United States

Biotechace Aug. 16 at 10:51 PM

$TARS Gurufocus predicts annual earnings per share of $10.99 in 2030

1 · Reply

Creyedr Aug. 14 at 7:34 PM

$TARS let it dip so I can buy a lot more

1 · Reply

TickrTalk0007 Aug. 13 at 2:52 AM

$TARS How does clearing blepharitis treat cataract? you need a new surgeon

3 · Reply

SouthHaus Aug. 12 at 12:13 PM

$TARS Was referred to ophthalmologist-surgeon yesterday, re: an intensifying right eye cataract. He looked and said, “Let’s clear up the blepharitis first and see if that makes a difference.” Then he started to ask if I had seen the commercial about eyelid mites. I surprised him by naming XDEMVY and its manufacturer. He asked, “How do you know…?” I told him I own shares of Tarsus. He smiled. A strange thing I’ll mention here. Dr. said he’d call in the script. I checked with him to make sure the script was going to be directed to my local CVS. He said, “You won’t get it there. I have to call the script into a Walgreen’s specialty pharmacy which will fill the prescription. Don’t be at all surprised when you get a confirmation phone call from a 919 (Raleigh) area code.

1 · Reply

DonCorleone77 Aug. 12 at 11:58 AM

$TARS Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer Oppenheimer analyst Mazahir Alimohamed raised the firm's price target on Tarsus Pharmaceuticals to $100 from $97 and keeps an Outperform rating on the shares. The firm is updating its model for Tarsus following Q2 results, adding epidemiology-based revenue builds for IRX-101 in intravitreal antisepsis and ALK-001 in Stargardt disease, and reflecting the pending $450M Alkeus acquisition and $125M private placement.

1 · Reply

MichaelObamaa Aug. 12 at 1:49 AM

$TARS really regretted not buying at 59

2 · Reply

Biotechace Aug. 11 at 9:38 PM

$TARS we should be in the 70's tomorrow. Chart looking good. This is what anyone that bought those December puts the Dickr recommended feels like right now! TARS to the moon! Rock on!

0 · Reply

Mondose Aug. 10 at 8:24 PM

$TARS Price just went up through 21 week EMA. Momentum points to more upward movement. Price is now poised to work up into triple digits. These are my opinions only and not investment advice.

0 · Reply

MichaelObamaa Aug. 10 at 2:41 PM

$TARS anyone trading the up and down action?

3 · Reply

DonCorleone77 Aug. 10 at 11:22 AM

$TARS Tarsus Pharmaceuticals price target raised to $100 from $98 at Mizuho Mizuho raised the firm's price target on Tarsus Pharmaceuticals to $100 from $98 and keeps an Outperform rating on the shares.

0 · Reply

Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer

2026-08-10T11:27:15.000Z - 9 days ago

Tarsus Pharmaceuticals price target raised to $100 from $98 at Mizuho

2026-08-06T13:21:19.000Z - 13 days ago

Tarsus to acquire Alkeus Pharmaceuticals for $450M upfront, up to $800M total

2026-08-06T12:18:03.000Z - 13 days ago

Tarsus Pharmaceuticals reports Q2 EPS (43c), consensus (20c)

2026-08-06T12:10:51.000Z - 13 days ago

Tarsus Pharmaceuticals announces $125M private placement

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Tarsus Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Tarsus Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Tarsus Pharmaceuticals Slides: Q2 2026

Aug 6, 2026, 7:58 AM EDT - 13 days ago

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

Aug 6, 2026, 7:03 AM EDT - 13 days ago

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Aug 6, 2026, 7:02 AM EDT - 13 days ago

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Aug 6, 2026, 7:01 AM EDT - 13 days ago

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Aug 5, 2026, 8:02 PM EDT - 13 days ago

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

2026-08-03T11:32:20.000Z - 16 days ago

Tarsus Pharmaceuticals price target lowered to $98 from $100 at Mizuho

2026-07-31T11:32:26.000Z - 19 days ago

Tarsus Pharmaceuticals price target lowered to $98 from $100 at Mizuho

2026-07-21T12:06:25.000Z - 4 weeks ago

Tarsus Pharmaceuticals price target lowered to $89 from $90 at Guggenheim

2026-07-13T20:15:48.000Z - 5 weeks ago

Tarsus Pharmaceuticals chief commercial officer Aziz Mottiwala to depart

Jul 13, 2026, 4:05 PM EDT - 5 weeks ago

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Jul 8, 2026, 4:30 PM EDT - 5 weeks ago

Tarsus Pharmaceuticals Transcript: M&A announcement

Jul 8, 2026, 4:30 PM EDT - 5 weeks ago

Tarsus Pharmaceuticals Press release: M&A announcement

Jul 8, 2026, 4:30 PM EDT - 5 weeks ago

Tarsus Pharmaceuticals Slides: M&A announcement

2026-07-08T20:20:21.000Z - 5 weeks ago

Tarsus Pharmaceuticals acquires iRenix Medical

Jul 8, 2026, 4:05 PM EDT - 5 weeks ago

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Jul 8, 2026, 7:00 AM EDT - 6 weeks ago

Tarsus Pharmaceuticals Slides: Corporate presentation

2026-07-01T17:05:20.000Z - 6 weeks ago

Culper Research announces Tarsus Pharmaceuticals short position

Jun 3, 2026, 11:40 AM EDT - 2 months ago

Tarsus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 11:00 AM EDT - 2 months ago

Tarsus Pharmaceuticals Transcript: 46th Annual William Blair Growth Stock Conference

May 28, 2026, 4:30 PM EDT - 2 months ago

Tarsus to Participate in Upcoming Investor Conferences

May 26, 2026, 3:30 PM EDT - 3 months ago

Tarsus Pharmaceuticals Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 19, 2026, 11:00 AM EDT - 3 months ago

Tarsus Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 14, 2026, 8:30 AM EDT - 3 months ago

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

May 12, 2026, 6:40 PM EDT - 3 months ago

Tarsus Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T00:43:07.000Z - 3 months ago

Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)

May 6, 2026, 4:30 PM EDT - 3 months ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Tarsus Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Tarsus Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Tarsus Pharmaceuticals Slides: Q1 2026

May 6, 2026, 4:05 PM EDT - 3 months ago

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Tarsus Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Tarsus Pharmaceuticals Proxy statement: Proxy filing

2026-04-24T11:48:37.000Z - 4 months ago

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

2026-03-31T14:23:18.000Z - 5 months ago

Tarsus Pharmaceuticals doses first participant in TP-05 trial

Mar 31, 2026, 8:30 AM EDT - 5 months ago

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

2026-03-25T19:50:14.000Z - 5 months ago

Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho

2026-03-23T13:20:58.000Z - 5 months ago

Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval

Mar 23, 2026, 8:30 AM EDT - 5 months ago

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Mar 11, 2026, 12:30 PM EDT - 5 months ago

Tarsus Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 2:30 PM EST - 6 months ago

Tarsus Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-25T13:10:18.000Z - 6 months ago

Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer

Feb 23, 2026, 4:30 PM EST - 6 months ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Tarsus Pharmaceuticals Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Tarsus Pharmaceuticals Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Tarsus Pharmaceuticals Slides: Q4 2025

Feb 18, 2026, 8:30 AM EST - 6 months ago

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

Feb 17, 2026, 4:30 PM EST - 6 months ago

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

Nov 11, 2025, 2:30 PM EST - 10 months ago

Tarsus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:30 PM EST - 10 months ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Tarsus Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Tarsus Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Tarsus Pharmaceuticals Slides: Q3 2025

Nov 4, 2025, 4:05 PM EST - 10 months ago

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Oct 28, 2025, 5:00 PM EDT - 10 months ago

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Sep 3, 2025, 9:30 AM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Slides: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Jul 30, 2025, 5:00 PM EDT - 1 year ago

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jun 9, 2025, 1:20 PM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: 45th Annual William Blair Growth Stock Conference

May 27, 2025, 10:30 AM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 20, 2025, 3:00 PM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 6:40 PM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 5, 2025, 6:27 AM EDT - 1 year ago

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

ELAN

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Tarsus Pharmaceuticals Slides: Q1 2025

May 1, 2025, 4:05 PM EDT - 1 year ago

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

May 1, 2025, 3:00 PM EDT - 1 year ago

Tarsus Pharmaceuticals Slides: Corporate Presentation

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 24, 2025, 5:00 PM EDT - 1 year ago

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

$Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting$

Apr 22, 2025, 8:31 AM EDT - 1 year ago

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

Mar 12, 2025, 9:49 PM EDT - 1 year ago

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Mar 12, 2025, 4:12 PM EDT - 1 year ago

Tarsus Announces Proposed $100.0 Million Public Offering

Mar 11, 2025, 11:00 AM EDT - 1 year ago

Tarsus Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 6, 2025, 5:00 PM EST - 1 year ago

Tarsus to Participate in Upcoming Investor Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Annual report: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Earnings release: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Slides: Q4 2024

Feb 20, 2025, 5:00 PM EST - 1 year ago

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Feb 12, 2025, 10:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 9:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 14, 2025, 11:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Transcript: Investor Update

Jan 14, 2025, 11:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Press release: Investor Update

Jan 14, 2025, 11:00 AM EST - 1 year ago

Tarsus Pharmaceuticals Slides: Investor Update

Jan 13, 2025, 8:30 AM EST - 1 year ago

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Nov 13, 2024, 4:30 PM EST - 1 year ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Tarsus Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Tarsus Pharmaceuticals Earnings release: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Nov 6, 2024, 4:30 PM EST - 1 year ago

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Oct 2, 2024, 9:00 AM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: UBS Virtual Ophthalmology Day

Sep 25, 2024, 5:00 PM EDT - 2 years ago

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

Sep 4, 2024, 2:15 PM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: 2024 Wells Fargo Healthcare Conference

Aug 28, 2024, 5:00 PM EDT - 2 years ago

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings release: Q2 2024

Jul 29, 2024, 4:30 PM EDT - 2 years ago

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 10, 2024, 2:00 PM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

Jun 4, 2024, 4:20 PM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: The 44th Annual William Blair Growth Stock Conference

May 15, 2024, 4:55 PM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: BofA Securities 2024 Health Care Conference

May 9, 2024, 5:00 PM EDT - 2 years ago

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

May 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Quarterly report: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Tarsus Pharmaceuticals Earnings release: Q1 2024

May 8, 2024, 4:05 PM EDT - 2 years ago

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

May 1, 2024, 5:00 PM EDT - 2 years ago

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Tarsus Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2024, 8:30 AM EDT - 2 years ago

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

Mar 13, 2024, 9:30 AM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: Guggenheim 5th Annual Healthy Altitudes Summit

Mar 12, 2024, 3:05 PM EDT - 2 years ago

Tarsus Pharmaceuticals Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tarsus to Participate at Upcoming Investor Conferences

Mar 5, 2024, 8:30 AM EST - 2 years ago

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Mar 1, 2024, 12:07 AM EST - 2 years ago

Tarsus Announces Pricing of $100.0 Million Public Offering

Feb 27, 2024, 8:00 AM EST - 2 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

Tarsus Pharmaceuticals Annual report: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

Tarsus Pharmaceuticals Earnings release: Q4 2023

Feb 27, 2024, 6:00 AM EST - 2 years ago

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

Feb 22, 2024, 8:00 AM EST - 2 years ago

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

Feb 20, 2024, 5:00 PM EST - 2 years ago

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

Feb 8, 2024, 1:00 PM EST - 2 years ago

Tarsus Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 5:00 PM EST - 2 years ago

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

Dec 11, 2023, 8:00 AM EST - 2 years ago

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

Dec 11, 2023, 7:00 AM EST - 2 years ago

Tarsus Pharmaceuticals Slides: Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Mites Topline Data Presentation

Nov 9, 2023, 4:30 PM EST - 3 years ago

Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 3 years ago

Tarsus Pharmaceuticals Quarterly report: Q3 2023

Nov 9, 2023, 4:30 PM EST - 3 years ago

Tarsus Pharmaceuticals Earnings release: Q3 2023

Nov 9, 2023, 4:05 PM EST - 3 years ago

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Nov 9, 2023, 7:00 AM EST - 3 years ago

Tarsus Pharmaceuticals Registration statement: Registration Filing

Nov 1, 2023, 6:35 PM EDT - 3 years ago

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

Biotechace Aug. 16 at 10:51 PM

$TARS Gurufocus predicts annual earnings per share of $10.99 in 2030

1 · Reply

Creyedr Aug. 14 at 7:34 PM

$TARS let it dip so I can buy a lot more

1 · Reply

TickrTalk0007 Aug. 13 at 2:52 AM

$TARS How does clearing blepharitis treat cataract? you need a new surgeon

3 · Reply

SouthHaus Aug. 12 at 12:13 PM

1 · Reply

DonCorleone77 Aug. 12 at 11:58 AM

1 · Reply

MichaelObamaa Aug. 12 at 1:49 AM

$TARS really regretted not buying at 59

2 · Reply

Biotechace Aug. 11 at 9:38 PM

$TARS we should be in the 70's tomorrow. Chart looking good. This is what anyone that bought those December puts the Dickr recommended feels like right now! TARS to the moon! Rock on!

0 · Reply

Mondose Aug. 10 at 8:24 PM

$TARS Price just went up through 21 week EMA. Momentum points to more upward movement. Price is now poised to work up into triple digits. These are my opinions only and not investment advice.

0 · Reply

MichaelObamaa Aug. 10 at 2:41 PM

$TARS anyone trading the up and down action?

3 · Reply

DonCorleone77 Aug. 10 at 11:22 AM

0 · Reply

TickrTalk0007 Aug. 8 at 12:21 AM

$TARS but puts for Dec 2026 and thank me later. Tickr Out✌🏽

2 · Reply

Mikelonggggggggg Aug. 7 at 11:24 AM

$ZVRA Neil could be going on a shopping spree like $TARS

2 · Reply

TickrTalk0007 Aug. 6 at 8:59 PM

$TARS spend $162M to make $170M and dilute to the tune of $350M🤪

2 · Reply

STACKD0E Aug. 6 at 6:47 PM

$ENOV $TARS $MGRT $IOVA $CULP 🙃 ✨️

0 · Reply

CH_Expat Aug. 6 at 4:14 PM

$TARS Out here, just for transparency. This add-ons are not the stuff I a m looking for. Mild win. GLTA.

3 · Reply

TickrTalk0007 Aug. 6 at 2:56 PM

$TARS add $125M PIPE to the $218M financing and you have $343M worth of dilution

0 · Reply

notreload_ai Aug. 6 at 2:19 PM

$TARS to acquire Alkeus for up to $800M, adding late-stage oral therapy for Stargardt disease – a rare eye disorder with no approved treatments. https://notreload.xyz/xy/tarsus-acquires-alkeus-in-800m-deal-for-stargardt-drug/

1 · Reply

TickrTalk0007 Aug. 6 at 2:15 PM

$TARS the biggest risk now if a Phase 3 data readout in retina...very risky actually

0 · Reply

TickrTalk0007 Aug. 6 at 2:05 PM

$TARS totally insane to get an oral when you just bought an intravitreal antiseptic that didnt fit your sales call points...now this deal with an oral tx instead of an IVT..lol...why would you do a licensing structure and pay $450M before a Ph 3 data readout for a distressed company? The CEO and the Board needs to get fired....totally blowing through investor money and diluting for $218M with the last 2 deals that make ZERO sense. I can see why the previous CCO left.

1 · Reply

PivotNova Aug. 6 at 1:19 PM

$TARS buying an eye care pharma name to expand the pipeline. Private placement oversubscribed, so the street is buying the story. Need to see if the integration actually delivers.

0 · Reply

EarningsInsider Aug. 6 at 1:02 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-tarsus-pharmaceuticals-inc-stock/ $TARS Tarsus Pharmaceuticals Earnings Transcript

0 · Reply

ElmerFuddz Aug. 6 at 12:41 PM

$TARS Bought the dip.

0 · Reply

Market Cap	3.10B
Revenue (ttm)	451.36M
Net Income (ttm)	-66.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14.72%
Debt to Equity Ratio	0.21

Volume	628,800
Avg Vol	1,019,210
Day's Range	N/A - N/A
Shares Out	43.88M
Stochastic %K	97%
Beta	0.53
Analysts	Strong Sell
Price Target	$90.50